Zeo ScientifiX, Inc. (ZEOX) Form 8-K — Jul 8, 2026
Zeo ScientifiX reported exceptional financial results for the quarter ended April 30, 2026, with revenue growing 124.6% year-over-year to $2,581,000 compared to $1,149,000 in the prior year. For the six months ended April 30, 2026, revenue reached $4,027,000, representing a 79.9% increase from the $2,239,000 reported in the same period of 2025. The growth was driven primarily by increased sales of allogenic biologic products and expanded physician adoption in Florida. The company noted significant commercial momentum across its regenerative biologics portfolio, supported by educational initiatives and conferences.
Key figures
- Revenue
- 2581000
- Net Income
- -1000000
- Revenue Yoy
- 124.6%
- Gross Margin
- 80.0%
- Revenue Six Months
- 4027000
- Revenue Six Months Growth
- 79.9%
- Net Loss Six Months Prior Year
- 2600000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.